Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 10/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.37 |
| ▸ | BIRC8 | Q96P09 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300491 | 1.00 | XIAP (0.41) | XIAPCASP1CASP3CASP8CTSL | |
| SCHEMBL1300499 | 1.00 | XIAP (0.41) | XIAPCASP1CASP3CASP8CTSL | |
| SCHEMBL1300496 | 1.00 | XIAP (0.41) | XIAPCASP1CASP3CASP8CTSL | |
| SCHEMBL12109045 | 0.91 | CTSK (0.39) | XIAPCTSLCTSBCTSSCTSK | |
| SCHEMBL31384828 | 0.88 | XIAP (0.43) | XIAPCASP1CTSLCTSBCTSS | |
| SCHEMBL12125844 | 0.88 | XIAP (0.57) | XIAPBIRC2BIRC8 | |
| SCHEMBL31384842 | 0.87 | XIAP (0.40) | XIAPCASP1CTSLCTSBCTSS | |
| SCHEMBL31384893 | 0.86 | XIAP (0.39) | XIAPCASP1CTSLCTSBCTSS | |
| SCHEMBL1299626 | 0.85 | CASP1 (0.47) | XIAPCASP1CASP3CASP8CTSL | |
| SCHEMBL1299624 | 0.85 | CASP1 (0.47) | XIAPCASP1CASP3CASP8CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | XIAP 1017/4885CASP1 4516/4885CASP3 4773/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | XIAP 1017/4885CASP1 4516/4885CASP3 4773/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | XIAP 1017/4885CASP1 4516/4885CASP3 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.